Government Contracts	3 Months Ended
Mar. 31, 2026
Contractors [Abstract]
Government Contract	8. Government Contract BARDA In July 2018, the Company was awarded a contract from Biomedical Advanced Research and Development Authority (“BARDA”) of up to $44.2 million to develop tebipenem HBr for the treatment of cUTI caused by antibiotic resistant Gram-negative bacteria and for assessment against biodefense pathogens. The original award committed initial funding of $15.7 million over a three-year base period from July 1, 2018 to June 30, 2021 for cUTI development activities. Through a number of contract modifications and the exercise of additional contract options by BARDA, the committed funding was increased to $65.6 million as of March 31, 2026, and the period of performance extended through October 31, 2026. The Company did not recognize any grant revenue under the BARDA agreement for the three months ended March 31, 2026 and recognized $0.7 million of grant revenue for the three months ended March 31, 2025. As of March 31, 2026, of the $65.6 million of committed funding, the Company has cumulatively recognized $65.1 million of grant revenue under the BARDA agreement. The Company does not anticipate receiving the remaining funding from BARDA.

Government Contracts

3 Months Ended

Mar. 31, 2026

BARDA

In July 2018, the Company was awarded a contract from Biomedical Advanced Research and Development Authority (“BARDA”) of up to $44.2 million to develop tebipenem HBr for the treatment of cUTI caused by antibiotic resistant Gram-negative bacteria and for assessment against biodefense pathogens. The original award committed initial funding of $15.7 million over a three-year base period from July 1, 2018 to June 30, 2021 for cUTI development activities. Through a number of contract modifications and the exercise of additional contract options by BARDA, the committed funding was increased to $65.6 million as of March 31, 2026, and the period of performance extended through October 31, 2026.

The Company did not recognize any grant revenue under the BARDA agreement for the three months ended March 31, 2026 and recognized $0.7 million of grant revenue for the three months ended March 31, 2025.

As of March 31, 2026, of the $65.6 million of committed funding, the Company has cumulatively recognized $65.1 million of grant revenue under the BARDA agreement. The Company does not anticipate receiving the remaining funding from BARDA.